House Erbitux Probe Widens To Firms That Considered ImClone Partnership
Executive Summary
The House Energy & Commerce Committee is widening its Erbitux investigation to include several companies who considered partnering with ImClone on the colorectal cancer drug
You may also be interested in...
ImClone Erbitux Hearing Will Include Five FDAers Under Subpoena
The House Energy & Commerce/Oversight Subcommittee has subpoenaed five FDA witnesses to appear at a June 13 hearing on issues surrounding the refuse-to-file letter for ImClone's Erbitux
ImClone Erbitux Hearing Will Include Five FDAers Under Subpoena
The House Energy & Commerce/Oversight Subcommittee has subpoenaed five FDA witnesses to appear at a June 13 hearing on issues surrounding the refuse-to-file letter for ImClone's Erbitux
FDA Refuse-To-File Policy Records Requested Under House ImClone Probe
The House Commerce/Oversight Subcommittee is asking FDA to provide records relating to its policy on refuse-to-file letters, as part of its broadening investigation into ImClone